Immediate and one-year outcome of percutaneous intervention of saphenous vein graft disease with paclitaxel-eluting stents.
The aim of this study was to evaluate the outcome after paclitaxel-eluting stent implantation in 40 patients with 52 saphenous vein graft lesions. By Kaplan-Meier estimates, the probability of major adverse cardiac event-free survival for 1 year was 92.5%. A paclitaxel-eluting stent for saphenous vein graft disease appears to be feasible and safe, with a low rate of reintervention at 1 year, but late follow-up is needed to confirm these observations.
Tsuchida
Keiichi
K
Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands.
Ong
Andrew T L
AT
Aoki
Jiro
J
van Mieghem
Carlos A G
CA
Rodriguez-Granillo
Gastón A
GA
Valgimigli
Marco
M
Sianos
Georgios
G
Regar
Evelyn
E
McFadden
Eugène P
EP
van der Giessen
Willem J
WJ
de Feyter
Pim J
PJ
de Jaegere
Peter P T
PP
van Domburg
Ron T
RT
Serruys
Patrick W
PW
D000368:Aged; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000000981:diagnostic imaging / Q000517:prevention & control*; D005260:Female; D005500:Follow-Up Studies; D006083:Graft Occlusion, Vascular / Q000000981:diagnostic imaging / Q000517:prevention & control*; D006801:Humans; D008297:Male; D017239:Paclitaxel / Q000008:administration & dosage*; D011446:Prospective Studies; D012501:Saphenous Vein; D015607:Stents; D016896:Treatment Outcome
D017239:Paclitaxel